Response to Letter to the Editor from Zandee and Links: "Metastatic Differentiated Thyroid Cancer Survival Is Unaffected by Mode of Preparation for I Administration".
作者信息
Gomes-Lima Cristiane J, Chittimoju Sanjita, Wehbeh Leen, Dia Sunita, Pagadala Prathyusha, Al-Jundi Mohammad, Jhawar Sakshi, Tefera Eshetu, Mete Mihriye, Klubo-Gwiezdzinska Joanna, Van Nostrand Douglas, Jonklaas Jacqueline, Wartofsky Leonard, Burman Kenneth D
机构信息
MedStar Clinical Research Center, MedStar Health Research Institute (MHRI), Hyattsville, MD 20782-2031, USA.
Section of Endocrinology, MedStar Washington Hospital Center, Washington, DC 20010, USA.
出版信息
J Endocr Soc. 2023 Jan 25;7(3):bvad005. doi: 10.1210/jendso/bvad005. eCollection 2023 Jan 6.
Abstract
摘要
相似文献
1
Response to Letter to the Editor from Zandee and Links: "Metastatic Differentiated Thyroid Cancer Survival Is Unaffected by Mode of Preparation for I Administration".对赞迪和林克斯致编辑信的回复：“转移性分化型甲状腺癌的生存不受碘给药准备方式的影响”。
J Endocr Soc. 2023 Jan 25;7(3):bvad005. doi: 10.1210/jendso/bvad005. eCollection 2023 Jan 6.
2
Letter to the Editor From Zandee and Links: "Metastatic Differentiated Thyroid Cancer Survival Is Unaffected by Mode of Preparation for I Administration".赞迪和林克斯致编辑的信：“分化型甲状腺癌转移患者的生存不受碘给药准备方式的影响”。
J Endocr Soc. 2023 Jan 25;7(3):bvad004. doi: 10.1210/jendso/bvad004. eCollection 2023 Jan 6.
3
Metastatic Differentiated Thyroid Cancer Survival Is Unaffected by Mode of Preparation for I Administration.转移性分化型甲状腺癌的生存率不受碘给药准备方式的影响。
J Endocr Soc. 2022 Mar 2;6(5):bvac032. doi: 10.1210/jendso/bvac032. eCollection 2022 May 1.
4
Letter to the editor regarding "Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival".
Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3622-3623. doi: 10.1007/s00259-022-05869-8. Epub 2022 Jun 15.
5
Response to Letter to the Editor: "Time to Separate Persistent From Recurrent Differentiated Thyroid Cancer: Different Conditions With Different Outcomes".
J Clin Endocrinol Metab. 2019 Nov 1;104(11):5110-5111. doi: 10.1210/jc.2019-00851.
6
Letter to the Editor Regarding the Article "(124)I PET/CT in Patients with Differentiated Thyroid Cancer: Clinical and Quantitative Image Analysis".
Thyroid. 2016 Aug;26(8):1141-2. doi: 10.1089/thy.2016.0180. Epub 2016 Jun 28.
7
Letter to the Editor: "Time to Separate Persistent From Recurrent Differentiated Thyroid Cancer: Different Conditions With Different Outcomes".
J Clin Endocrinol Metab. 2019 Nov 1;104(11):5108-5109. doi: 10.1210/jc.2019-00634.
8
Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer.重组人促甲状腺激素在分化型甲状腺癌远处转移患者治疗中的潜在应用。
Endocr Pract. 2013 Jan-Feb;19(1):139-48. doi: 10.4158/EP12244.RA.
9
Letter to the Editor: What Is the Role of Serum Thyroglobulin Measurement in Patients With Differentiated Thyroid Cancer Treated Without Radioactive Iodine?致编辑的信：血清甲状腺球蛋白检测在未接受放射性碘治疗的分化型甲状腺癌患者中的作用是什么？
J Clin Endocrinol Metab. 2017 Jun 1;102(6):2113-2114. doi: 10.1210/jc.2016-3983.
10
Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation.血清血管内皮生长因子水平在转移性分化型甲状腺癌中升高，但短期促甲状腺激素刺激不会使其升高。
J Clin Endocrinol Metab. 2002 Apr;87(4):1737-42. doi: 10.1210/jcem.87.4.8388.
本文引用的文献
1
Letter to the Editor From Zandee and Links: "Metastatic Differentiated Thyroid Cancer Survival Is Unaffected by Mode of Preparation for I Administration".赞迪和林克斯致编辑的信：“分化型甲状腺癌转移患者的生存不受碘给药准备方式的影响”。
J Endocr Soc. 2023 Jan 25;7(3):bvad004. doi: 10.1210/jendso/bvad004. eCollection 2023 Jan 6.
2
Metastatic Differentiated Thyroid Cancer Survival Is Unaffected by Mode of Preparation for I Administration.转移性分化型甲状腺癌的生存率不受碘给药准备方式的影响。
J Endocr Soc. 2022 Mar 2;6(5):bvac032. doi: 10.1210/jendso/bvac032. eCollection 2022 May 1.
3
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH.使用重组或内源性 TSH 的转移性甲状腺癌患者的结局无差异。
Eur J Endocrinol. 2020 Oct;183(4):411-417. doi: 10.1530/EJE-20-0088.
4
Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH.对于准备接受放射性碘治疗的伴有远处转移的甲状腺癌患者，甲状腺激素抑制或重组人 TSH 准备后，其 5 年生存率相似。
J Clin Endocrinol Metab. 2011 Jul;96(7):2105-11. doi: 10.1210/jc.2011-0305. Epub 2011 May 11.
Zotero 插件